More Generics Companies Targeting Teva’s Copaxone 40 mg

Drug Industry Daily
A A
Generics manufacturers Mylan, Momenta and Sandoz have joined Dr. Reddy’s Laboratories as some of the first to announce patent challenges against Teva’s blockbuster multiple sclerosis drug Copaxone in the newer 40 mg version.

To View This Article:

Login

Subscribe To Drug Industry Daily